Ar­ray MEK/BRAF com­bo beats out Roche ri­val in PhI­II melanoma OS show­down

Ar­ray Bio­Phar­ma’s MEK/BRAF in­hibitor com­bo hand­i­ly beat out Roche’s Zelb­o­raf on over­all sur­vival scores among a group of pa­tients suf­fer­ing from ad­vanced melanoma with …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.